Single answer

Is Alkermes plc (ALKS) a buy or sell?

4starter turns market data into one clear verdict you can act on.

Buy
$31.04
-2.35 (-7.04%)
Quote updated: 2026-02-25 21:00 UTC
Trend today
-7.04%
Down today
Volume vs avg
110.17%
2.10x over average
Target gap
49.42%
above current price
Signal updated
2026-02-25 19:23 UTC
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Add to watchlist

Create a free account to save tickers and track your signals.

Log in to turn on watchlist alerts.

Decision snapshot

Everything you need to act fast, in one glance.

4starter signal
Buy
80%
Score
Confidence score
Higher scores mean stronger signal alignment.

Powered by momentum, volatility, and trend inputs.

Analyst target gap
49.42%
$15.34 above current price

Consensus target $46.38.

Volume vs average
110.17%
over average

3.9M vs 1.9M average (2.10x normal).

What is the conclusion?

Right now our advanced algorithms say:

YES

$1 invested is now $0.99 or -0.84%

(In 16 weeks 2 days 19 hours 54 minutes and 34 seconds .)

Do analysts agree?

We compare consensus targets with today's price.

YES

Consensus target for Alkermes plc is $46.38, which is $15.34 (49.42%) above the current price today's price.

Low target: $43.00 | High target: $56.00

Latest analyst updates

Recent rating and price target changes for this stock.

2026-02-23 | Wolfe Research | Target 45.00
2025-10-27 | Mizuho Securities | Target 45.00
2025-10-23 | Piper Sandler | Target 45.00

Company snapshot

A quick overview of the business and its public profile.

Alkermes plc a biopharmaceutical company researches develops and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States Ireland and internationally Its marketed products include ARISTADA an intramuscular injectable suspension for the treatment of schizophrenia VIVITROL for the treatment of alcohol and prevention of opioid dependence RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder XEPLION INVEGA TRINZA and TREVICTA to treat schizophrenia and schizoaffective and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults including clinically isolated syndrome relapsingremitting and active secondary progressive diseases The company is also developing LYBALVI an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder and nemvaleukin alfa an engineered fusion protein to expand tumorkilling immune cells and to avoid the activation of immunosuppressive cells It has collaboration agreements primarily with Janssen Pharmaceutica NV Janssen Pharmaceutica Inc and Janssen Pharmaceutica International Alkermes plc was founded in 1987 and is headquartered in Dublin Ireland

Website: https://www.alkermes.com

Rates and inflation backdrop

US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.

Inflation sensitivity

Debt ratio: 0.03. Cash flow to debt ratio: 7.56. Net profit margin: 22.27%. Inflation risk score: low (0.00/1).

Dividend history check

We cannot find any recorded dividends paid in our systems.

Trading liquidity

Yes, the average daily trading liquidity for Alkermes plc is $67.3M. You should therefore be able to get in and out of your positions relatively fast.

10-year return check

On Alkermes plc, 2016-02-26 had a stock price of $33.61. If you invested back then, your return now would be a loss of $2.57 per share or 7.65%.

Why this answer

We combine price momentum, volatility, and trend signals to simplify the decision to one word.

1

Signal engine scans price, trend, and momentum indicators.

2

Targets and sentiment are checked against the live quote.

3

We keep the output simple: buy, sell, or hold.

Analyst consensus

How Wall Street targets compare to today's price.

$46.38
$15.34 (49.42%) above the current price
Range: $43.00 - $56.00

FAQ

Today's 4starter signal is Buy. That means the current data favors upside over downside.

Quotes and targets refresh throughout the trading day, with the latest timestamp shown on the page.

It blends momentum, trend, and volatility indicators into a single decision-oriented verdict.